Drug
Relacorilant Once Daily
Relacorilant Once Daily: highest development phase Phase 2, developed by Corcept Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Corcept Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Relacorilant 150 mg once daily (QD) NCT06906341 | Phase 2 | Ovarian Cancer |
Latest
No recent events.
Follow Relacorilant Once Daily on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.